Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics

Prostate-Cancer Mortality at 11 Years of Follow-up

Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., KWIATKOWSKI, M. K., Lujan, M., Lilja, H. G., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,241 · see citing works

Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer Patients

Ghezzi, P. (1994) · JAMA · doi:10.1001/jama.1994.03510440047031 · Cited by 618 · see citing works

Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005

Welch, H. G., & Albertsen, P. C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp278 · Cited by 578 · see citing works

Karnofsky Memorial Lecture. Natural history of small breast cancers.

Hellman, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2229 · Cited by 421 · see citing works

TEMPORAL TRENDS IN RATES OF PROSTATE CANCER: DECLINING INCIDENCE OF ADVANCED STAGE DISEASE, 1974 TO 1994

Newcomer, L. M., Stanford, J. L., Blumenstein, B. A., & Brawer, M. K. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64231-9 · Cited by 158 · see citing works

Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement

Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094 · see citing works

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement

U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-10-200911170-00008 · Cited by 1,685 · see citing works

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness

Welch, H. G., Prorok, P. C., O’Malley, A. J., & Kramer, B. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600249 · Cited by 698 · see citing works

Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319352 · Cited by 659 · see citing works

Trends in Incidence of Metastatic Prostate Cancer in the US

Desai, M. M., Cacciamani, G. E., Gill, K. S., Zhang, J., Liu, L., Abreu, A. L., & Gill, I. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2246 · Cited by 247 · see citing works

Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States

Kelly, S. P., Anderson, W. F., Rosenberg, P. S., & Cook, M. B. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.10.014 · Cited by 217 · see citing works

Epidemiologic Signatures in Cancer

Welch, H. G., Kramer, B. S., & Black, W. C. (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1905447 · Cited by 213 · see citing works

Molecular characterization of breast cancer CTCs associated with brain metastasis

Boral, D., Vishnoi, M., Liu, H. N., Yin, W., Sprouse, M. L., Scamardo, A. T., Hong, D. S., Tan, T. Z., Thiery, J. P., Chang, J. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00196-1 · Cited by 186 · see citing works

Reconsidering Prostate Cancer Mortality — The Future of PSA Screening

Welch, H. G., & Albertsen, P. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmms1914228 · Cited by 180 · see citing works

Mammography screening: A major issue in medicine

Autier, P., & Boniol, M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.002 · Cited by 181 · see citing works

Population-based screening for cancer: hope and hype

Shieh, Y., Eklund, M., Sawaya, G. F., Black, W. C., Kramer, B. S., & Esserman, L. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.50 · Cited by 147 · see citing works

Prostate Cancer Screening — A Perspective on the Current State of the Evidence

Pinsky, P. F., Prorok, P. C., & Kramer, B. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmsb1616281 · Cited by 124 · see citing works

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012

Pang, H., Wang, X., Stinchcombe, T. E., Wong, M. L., Cheng, P., Ganti, A. K., Sargent, D. J., Zhang, Y., Hu, C., Mandrekar, S. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.7088 · Cited by 118 · see citing works

Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA

Schafer, E. J., Jemal, A., Wiese, D., Sung, H., Kratzer, T. B., Islami, F., Dahut, W. L., & Knudsen, K. E. (2023) · European Urology · doi:10.1016/j.eururo.2022.11.023 · Cited by 114 · see citing works

A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE)

Anttinen, M., Ettala, O. O., Malaspina, S., Jambor, I., Sandell, M., Kajander, S. A., Rinta-Kiikka, I. C., Schildt, J., Saukko, E., Rautio, P., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.06.012 · Cited by 114 · see citing works

Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer

Preston, M. A., Batista, J. L., Wilson, K. M., Carlsson, S., Gerke, T. A., Sjoberg, D. D., Dahl, D. M., Sesso, H. D., Feldman, A. S., Gann, P. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7527 · Cited by 111 · see citing works

Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate

Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ouzzane, A., Ploussard, G., Azria, D., et al. (2016) · The French Journal of Urology · doi:10.1016/s1166-7087(16)30705-9 · Cited by 109 · see citing works

Trends in the Incidence of Fatal Prostate Cancer in the United States by Race

Kelly, S. P., Rosenberg, P. S., Anderson, W. F., Andreotti, G., Younes, N., Cleary, S. D., & Cook, M. B. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.011 · Cited by 106 · see citing works

Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohorts

Helgstrand, J. T., Røder, M. A., Klemann, N., Toft, B. G., Lichtensztajn, D. Y., Brooks, J. D., Brasso, K., Vainer, B., & Iversen, P. (2018) · Cancer · doi:10.1002/cncr.31384 · Cited by 103 · see citing works

Epidemiology of De Novo Metastatic Breast Cancer

Daily, K. C., Douglas, E. H., Romitti, P. A., & Thomas, A. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.01.017 · Cited by 90 · see citing works

Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography

Vlahiotis, A., Griffin, B., Stavros, A. T., & Margolis, J. M. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s150260 · Cited by 81 · see citing works

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Moschini, M., Carroll, P. R., Eggener, S. E., Epstein, J. I., Graefen, M., Montironi, R., & Parker, C. C. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.009 · Cited by 80 · see citing works

De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype

Press, D., Miller, M. E., Liederbach, E., Yao, K., & Huo, D. (2017) · Clinical and Experimental Metastasis · doi:10.1007/s10585-017-9871-9 · Cited by 72 · see citing works

NUSAP1 promotes invasion and metastasis of prostate cancer

Gordon, C. A., Gong, X., Ganesh, D., & Brooks, J. D. (2017) · Oncotarget · doi:10.18632/oncotarget.15604 · Cited by 72 · see citing works

Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis

Seisen, T., Vetterlein, M. W., Karabon, P., Jindal, T., Sood, A., Nocera, L., Nguyen, P. L., Choueiri, T. K., Trinh, Q., Menon, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.011 · Cited by 74 · see citing works

Prostate cancer screening and treatment: where have we come from and where are we going?

Albertsen, P. C. (2020) · British Journal of Urology · doi:10.1111/bju.15153 · Cited by 70 · see citing works

Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy

Puliti, D., Bucchi, L., Mancini, S., Paci, E., Baracco, S., Campari, C., Canuti, D., Cirilli, C., Collina, N., Conti, G. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.030 · Cited by 67 · see citing works

Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells

Phannasil, P., Ansari, I. H., Azzouny, M. E., Longacre, M. J., Rattanapornsompong, K., Burant, C., MacDonald, M. J., & Jitrapakdee, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.021 · Cited by 65 · see citing works

Secondary data sources for health services research in urologic oncology

Cole, A. P., Friedlander, D. F., & Trinh, Q. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.008 · Cited by 61 · see citing works

MgO nanoparticles coated with polyethylene glycol as carrier for 2-Methoxyestradiol anticancer drug

Alfaro, A., León, A. M., Guajardo-Correa, E., Reuquén, P., Torres, F. J., Mery, M. F., Segura, R., Zapata, P. A., & Orihuela, P. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214900 · Cited by 61 · see citing works

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population

Li, T., Chu, L. K., Wang, L. I., Moy, L. M., Brammer, M. G., Song, C., Green, M. C., Kurian, A. W., Gomez, S. L., & Clarke, C. A. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0791-9 · Cited by 60 · see citing works

Prostate cancer screening with prostate-specific antigen: A guide to the guidelines

Cabarkapa, S., Perera, M., McGrath, S. M., & Lawrentschuk, N. (2016) · Prostate International · doi:10.1016/j.prnil.2016.09.002 · Cited by 60 · see citing works

Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease

Finianos, A. N., Gupta, K., Clark, B., Simmens, S. J., & Aragon‐Ching, J. B. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.08.006 · Cited by 59 · see citing works

Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening

Machens, A., & Dralle, H. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0325 · Cited by 58 · see citing works

Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases

Bernstein, A., Shoag, J. E., Golan, R., Halpern, J. A., Schaeffer, E. M., Hsu, W.-C., Nguyen, P. L., Sedrakyan, A., Chen, R. C., Eggener, S. E., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.12.048 · Cited by 56 · see citing works

Statistics and pitfalls of trend analysis in cancer research: a review focused on statistical packages

Xu, J., Lin, Y., Yang, M., & Zhang, L. (2020) · Journal of Cancer · doi:10.7150/jca.43521 · Cited by 46 · see citing works

Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses

Dalela, D., Sun, M., Díaz, M., Karabon, P., Seisen, T., Trinh, Q., Menon, M., & Abdollah, F. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.04.012 · Cited by 46 · see citing works

Diagnostic characteristics of lethal prostate cancer

Helgstrand, J. T., Røder, M. A., Klemann, N., Toft, B. G., Brasso, K., Vainer, B., & Iversen, P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.007 · Cited by 46 · see citing works

Overview of guidelines on breast screening: Why recommendations differ and what to do about it

Jørgensen, K. J., Kalager, M., Barratt, A. L., Baines, C. J., Zahl, P., Brodersen, J., & Harris, R. (2016) · The Breast · doi:10.1016/j.breast.2016.08.002 · Cited by 44 · see citing works

Advances in Prognostic Methylation Biomarkers for Prostate Cancer

Lam, D., Clark, S. J., Stirzaker, C., & Pidsley, R. (2020) · Cancers · doi:10.3390/cancers12102993 · Cited by 43 · see citing works

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men

Basourakos, S. P., Gulati, R., Vince, R., Spratt, D. E., Lewicki, P., Hill, A., Nyame, Y. A., Cullen, J., Markt, S. C., Barbieri, C. E., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200031 · Cited by 42 · see citing works

Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis

Meglio, A. D., Freedman, R. A., Lin, N., Barry, W. T., Metzger, O., Keating, N. L., King, T. A., Sertoli, M. R., Boccardo, F., Winer, E. P., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3845-5 · Cited by 42 · see citing works

The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer

Seltzer, S., Corrigan, M. A., & O’Reilly, S. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104404 · Cited by 41 · see citing works

Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?

Heller, D. R., Chiu, A. S., Farrell, K., Killelea, B. K., & Lannin, D. R. (2019) · Cancers · doi:10.3390/cancers11040500 · Cited by 38 · see citing works

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement

Sundaresan, V. M., Smani, S., Rajwa, P., Renzulli, J., Sprenkle, P. C., Kim, I. Y., & Leapman, M. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.06.003 · Cited by 36 · see citing works

Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: Overall cost savings and improved quality of care to the us healthcare system.

Voigt, J. D., Dong, Y., Linder, V., & Zappala, S. M. (2017) · PubMed Central · doi:10.3909/riu0753 · Cited by 36 · see citing works

Truth or Spin? Disease Definition in Cancer Screening

Reid, L. (2017) · The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine · doi:10.1093/jmp/jhx006 · Cited by 35 · see citing works

A Content Analysis of Nonprofit Hospital Community Health Needs Assessments and Community Benefit Implementation Strategies in Philadelphia

Powell, R. E., Doty, A. M. B., Rising, K. L., Karp, D. N., Baehr, A., & Carr, B. G. (2017) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000000621 · Cited by 28 · see citing works

Trends in cancer incidence and mortality rates in the United States from 1975 to 2016

Yang, R., Zhou, Y., Wang, Y., Du, C., & Wu, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7841 · Cited by 27 · see citing works

Overdiagnosis in urologic cancer

Klotz, L. H. (2021) · World Journal of Urology · doi:10.1007/s00345-020-03523-2 · Cited by 27 · see citing works

Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer

File, D. M., Pascual, T., Deal, A. M., Wheless, A., Perou, C. M., Dees, E. C., & Carey, L. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06700-6 · Cited by 27 · see citing works

Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm

Halpern, J. A., Shoag, J. E., Mittal, S., Oromendia, C., Ballman, K. V., Hershman, D. L., Wright, J. D., Shih, Y. T., Nguyen, P. L., & Hu, J. C. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.08.092 · Cited by 27 · see citing works

Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice

Gaylis, F. D., Choi, J. E., Hamilton, Z. A., Dato, P. E., Cohen, E. S., Calabrese, R., Prime, H., Rosenbaum, A., & Kader, A. K. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.06.059 · Cited by 25 · see citing works

Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography

Jacklyn, G., McGeechan, K., Irwig, L., Houssami, N., Morrell, S. L., Bell, K., & Barratt, A. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4443-x · Cited by 25 · see citing works

Impact of Nanomedicine in Women's Metastatic Breast Cancer

Ashkarran, A. A., Lin, Z., Rana, J., Bumpers, H. L., Sempere, L. F., & Mahmoudi, M. (2023) · Small · doi:10.1002/smll.202301385 · Cited by 23 · see citing works

Tissue-based biomarkers in prostate cancer

Clinton, T. N., Bagrodia, A., Lotan, Y., Margulis, V., Raj, G. V., & Woldu, S. L. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1372687 · Cited by 23 · see citing works

Cancer Screening, Incidental Detection, and Overdiagnosis

Welch, H. G., & Bergmark, R. W. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad127 · Cited by 22 · see citing works

Role of surgery in oligometastatic prostate cancer

Jenjitranant, P., & Touijer, K. A. (2019) · Prostate International · doi:10.1016/j.prnil.2019.10.001 · Cited by 19 · see citing works

A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer

Yang, Z., Usama, S. M., Li, F., Burgess, K., & Li, Z. (2018) · MedChemComm · doi:10.1039/c8md00190a · Cited by 19 · see citing works

Plasma ghrelin O‐acyltransferase (GOAT) enzyme levels: A novel non‐invasive diagnosis tool for patients with significant prostate cancer

Gómez‐Gómez, E., Jiménez‐Vacas, J. M., Carrasco‐Valiente, J., Herrero‐Aguayo, V., Blanca, A., León‐González, A. J., Valero-Rosa, J., Fernández-Rueda, J. L., González-Serrano, T., López‐Miranda, J., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13845 · Cited by 19 · see citing works

Metastatic breast cancer: The Odyssey of personalization

Sonnenblick, A., Ponde, N. F., & Piccart, M. J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.002 · Cited by 18 · see citing works

European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance

Gómez‐Gómez, E., Carrasco‐Valiente, J., Blanca, A., Barco-Sánchez, B., Fernández-Rueda, J. L., Molina‐Abril, H., Valero-Rosa, J., Font, P., & Requena-Tapia, M. J. (2016) · Urology · doi:10.1016/j.urology.2016.11.004 · Cited by 18 · see citing works

Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment

Labbate, C. V., Klotz, L. H., Morrow, M., Cooperberg, M. R., Esserman, L. J., & Eggener, S. E. (2022) · The Journal of Urology · doi:10.1097/ju.0000000000002972 · Cited by 18 · see citing works

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer

Gómez‐Gómez, E., Jiménez‐Vacas, J. M., Pedraza‐Arévalo, S., L‐López, F., Herrero‐Aguayo, V., Hormaechea‐Agulla, D., Valero-Rosa, J., Ibáñez‐Costa, A., León‐González, A. J., Sánchez‐Sánchez, R., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091400 · Cited by 17 · see citing works

Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience

Che, W., Liu, J., Fu, T., Wang, X., & Lyu, J. (2022) · Current Oncology · doi:10.3390/curroncol29110660 · Cited by 17 · see citing works

Latest Progress in Risk-Adapted Surgery for Medullary Thyroid Cancer

Machens, A., Lorenz, K., Brandenburg, T., Führer, D., Weber, F., & Dralle, H. (2024) · Cancers · doi:10.3390/cancers16050917 · Cited by 17 · see citing works

PSA screening for prostate cancer

Sadi, M. V. (2017) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.63.08.722 · Cited by 17 · see citing works

Survival after recurrence of stage I–III breast, colorectal, or lung cancer

Hassett, M. J., Uno, H., Cronin, A. M., Carroll, N. M., Hornbrook, M. C., Fishman, P. A., & Ritzwoller, D. P. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2017.07.001 · Cited by 16 · see citing works

Progress in Low Dose Rate Brachytherapy for Prostate Cancer

McLaughlin, P. W., & Narayana, V. (2019) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.08.002 · Cited by 16 · see citing works

An Expanded Agenda for the Primary Prevention of Breast Cancer: Charting a Course for the Future

White, M. C., Kavanaugh-Lynch, M. (. H. E., Davis-Patterson, S., & Buermeyer, N. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17030714 · Cited by 17 · see citing works

The history of cancer screening

Jatoi, I., Anderson, W. F., Miller, A. B., & Brawley, O. W. (2019) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.12.006 · Cited by 15 · see citing works

Deceptive measures of progress in the NHS long-term plan for cancer: case-based vs. population-based measures

Oke, J. L., Brown, S. J., Senger, C., & Welch, H. G. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02308-9 · Cited by 15 · see citing works

Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting

Pilehvari, A., Kimmick, G. G., You, W., Bonilla, G., & Anderson, R. T. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01902-w · Cited by 14 · see citing works

Prostate cancer screening in Brazil: should it be done or not?

Busato, W. F. S., & Almeida, G. L. (2016) · International braz j urol · doi:10.1590/s1677-5538.ibju.2015.0709 · Cited by 14 · see citing works

Suppression of SIN3A by miR-183 Promotes Breast Cancer Metastasis

Davenport, M. L., Davis, M. R., Davenport, B. N., Crossman, D. K., Hall, A., Pike, J., Harada, S., Hurst, D. R., & Edmonds, M. D. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0508 · Cited by 14 · see citing works

The Precision Prostatectomy: “Waiting for Godot”

Sood, A., Abdollah, F., Jeong, W., & Menon, M. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.01.010 · Cited by 14 · see citing works

Hypoxia enhances motility and EMT through the Na+/H+ exchanger NHE-1 in MDA-MB-231 breast cancer cells

Takatani‐Nakase, T., Matsui, C., Hosotani, M., Omura, M., Takahashi, K., & Nakase, I. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.113006 · Cited by 13 · see citing works

Mohs Micrographic Surgery for Melanoma

Brodland, D. G. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.008 · Cited by 13 · see citing works

Breast Cancer, Chemokines, And Metastasis: A Search for Decoy Ligands of the CXCR4 Receptor

Mizejewski, G. J. (2018) · Journal of Neoplasms · doi:10.14302/issn.2639-1716.jn-18-2208 · Cited by 13 · see citing works

Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program

Cole, A. P., Krasnova, A., Ramaswamy, A., Fletcher, S. A., Friedlander, D. F., McNabb-Baltar, J. Y., Melnitchouk, N., Lipsitz, S. R., Sun, M., Kibel, A. S., et al. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00352 · Cited by 13 · see citing works

Overdiagnosis in the Age of Digital Cancer Screening

Brawley, O. W., & Paller, C. J. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa081 · Cited by 13 · see citing works

Prostate Cancer Prevention: Concepts and Clinical Trials

Hamilton, Z. A., & Parsons, J. K. (2016) · Current Urology Reports · doi:10.1007/s11934-016-0587-1 · Cited by 12 · see citing works

Genomic Characterization of De Novo Metastatic Breast Cancer

Mullangi, S., & Vasan, N. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.11.005 · Cited by 12 · see citing works

The evolving role of receptors as predictive biomarkers for metastatic breast cancer

Martínez-Pérez, C., Turnbull, A., & Dixon, J. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552138 · Cited by 13 · see citing works

Tumor-Penetrating Peptide Enhances Antitumor Effects of IL-24 Against Prostate Cancer

Yang, J., Yin, H. X., Yang, J., Wei, Y., Fang, L., Chai, D., Zhang, Q., & Zheng, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.12.002 · Cited by 12 · see citing works

Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer

Moschini, M., Shariat, S. F., Freschi, M., Soria, F., Abufaraj, M. M., Gandaglia, G., Dell’Oglio, P., Mattei, A., Damiano, R., Salonia, A., et al. (2017) · Urologia Internationalis · doi:10.1159/000454736 · Cited by 11 · see citing works

Correcting a decade of negative news about mammography

Schattner, E. J. (2019) · Clinical Imaging · doi:10.1016/j.clinimag.2019.03.011 · Cited by 11 · see citing works

De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence

Conte, B., Soldato, D., Razeti, M. G., Fregatti, P., de Azambuja, E., Schettini, F., Prat, A., Mastro, L. D., & Lambertini, M. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.10.001 · Cited by 11 · see citing works

POINT: Should Only Primary Care Physicians Provide Shared Decision-making Services to Discuss the Risks/Benefits of a Low-Dose Chest CT Scan for Lung Cancer Screening? Yes

Goodson, J. D. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.11.057 · Cited by 11 · see citing works

The Breast Cancer Screening “Arcade” and the “Whack-A-Mole” Efforts to Reduce Access to Screening

Kopans, D. B. (2017) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2017.06.002 · Cited by 11 · see citing works

The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment

Hewitt, K. C., Son, J. D., Glencer, A., Borowsky, A. D., Cooperberg, M. R., & Esserman, L. J. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0110 · Cited by 11 · see citing works

Integrative Bioinformatics Analysis Reveals That miR-524-5p/MEF2C Regulates Bone Metastasis in Prostate Cancer and Breast Cancer

Tian, Q., Lu, Y., Yan, B.-C., & Wu, C.-G. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5211329 · Cited by 10 · see citing works

Impacts on functional and oncological outcomes of Robotic-assisted Radical Prostatectomy 10 years after the US Preventive Service Taskforce recommendations against PSA screening

Moschovas, M. C., Abdel, J., Saikali, S., Sandri, M. F., Bhat, S., Rogers, T., Gamal, A., Loy, D., Patel, E., Reddy, S. K., et al. (2024) · International braz j urol · doi:10.1590/s1677-5538.ibju.2023.0530 · Cited by 10 · see citing works

What's new in screening in 2015?

Carlsson, S., & Roobol, M. J. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000321 · Cited by 10 · see citing works

The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients

Moschini, M., Soria, F., Briganti, A., & Shariat, S. F. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.52 · Cited by 10 · see citing works

Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer

Meyer, A. R., Joice, G. A., Allaf, M. E., Rowe, S. P., & Gorin, M. A. (2018) · Current Opinion in Urology · doi:10.1097/mou.0000000000000549 · Cited by 10 · see citing works

Trends in Metastatic Breast and Prostate Cancer.

Eby, P. R. (2016) · PubMed · doi:10.1056/nejmc1515983 · Cited by 9 · see citing works

Who and when should we screen for prostate cancer? Interviews with key opinion leaders

Carlsson, S., Leapman, M. S., Carroll, P. R., Schröder, F. H., Albertsen, P. C., Ilić, D., Barry, M. J., Frosch, D. L., & Vickers, A. J. (2015) · BMC Medicine · doi:10.1186/s12916-015-0526-x · Cited by 9 · see citing works

New agents for the management of resistant metastatic breast cancer

Anampa, J., & Sparano, J. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409206 · Cited by 8 · see citing works

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients

Sun, M., Lin, F., Chen, L.-J., Li, H., Lin, W., Du, H., Yang, X., & Li, M. (2021) · Current Oncology · doi:10.3390/curroncol28040214 · Cited by 8 · see citing works

Rethinking Screening for Breast Cancer and Prostate Cancer

Esserman, L. J. (2009) · JAMA · doi:10.1001/jama.2009.1498 · Cited by 516 · see citing works

Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer

Nyame, Y. A., Gulati, R., Tsodikov, A., Gore, J. L., & Etzioni, R. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa098 · Cited by 18 · see citing works

Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening

Yang, D. X., Makarov, D. V., Gross, C. P., & Yu, J. B. (2020) · Cancer Control · doi:10.1177/1073274820902267 · Cited by 5 · see citing works

Trends in Metastatic Breast and Prostate Cancer.

Eby, P. R. (2016) · PubMed · doi:10.1056/nejmc1515983 · Cited by 9 · see citing works

Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses

Dalela, D., Sun, M., Díaz, M., Karabon, P., Seisen, T., Trinh, Q., Menon, M., & Abdollah, F. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.04.012 · Cited by 46 · see citing works